CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Inclusion Criteria: * Primary refractory or relapsed AML (defined by 2016 World Health Organization \[WHO\] criteria) patients who are not suitable for or not willing to receive intensive chemotherapy as evaluated by the treating physician. Primary refractory disease is defined as: * Failure to achieve a CR, CRi, or mLFS (defined as \<5% Bone Marrow (BM) blasts) after receiving 1 or 2 cycles of remission induction chemotherapy. * Failure to achieve a CR, CRi, or MLFS (defined as \<5% BM blasts) after receiving 4 cycles of non-intensive chemotherapy or whose disease progressed at any time point during the treatment. * Participants with MDS (according to 2016 WHO criteria) who did not respond to treatment with azacitidine, decitabine, or combination of HMA with another drug or lost their response to initial therapy with HMA. * Eastern Cooperative Oncology Group (ECOG) performance status \<=2 * Adequate hepatic (serum total bilirubin \< 1.5 x ULN, Serum glutamic pyruvic transaminase (SGPT) and/or serum glutamate oxaloacetate transaminase (SGOT) \<2.5 x ULN) and renal function (creatinine \< 1.5mg/dL). * Participants must be willing and able to review, understand, and provide written consent before starting therapy. Exclusion Criteria: * Active signs or symptoms of central nervous system (CNS) involvement by malignancy (lumbar puncture \[LP\] not required). * Prior 7+3 remission induction chemotherapy for MDS or AML * More than 2 lines of prior non-intensive therapy. * Ne…